New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
20:25 EDTCOCO, COCO, NS, NS, LII, LII, BIP, BIP, NDAQ, NDAQ, LVLT, LVLT, GRA, GRA, CCE, CCE, BEAM, BEAM, RL, RL, MMP, MMP, HUM, HUM, EL, EL, CTSH, CTSH, AGN, AGN, ADP, ADP, TWX, TWX, MRK, MRKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Merck (MRK), consensus 88c; Time Warner (TWX), consensus $1.15; Automatic Data Processing (ADP), consensus 77c; Allergan (AGN), consensus $1.34; Cognizant (CTSH), consensus $1.06; Estee Lauder (EL), consensus $1.06; Humana (HUM), consensus 94c; Magellan Midstream (MMP), consensus 81c; Ralph Lauren (RL), consensus $2.51; Beam (BEAM), consensus 72c; Coca-Cola Enterprises (CCE), consensus 52c; W.R. Grace (GRA), consensus $1.19; Level 3 (LVLT), consensus 3c; Nasdaq (NDAQ), consensus 67c; Brookfield Infrastructure Partners (BIP), consensus 35c; Lazard (LAZ), consensus 61c; Arrow Electronics(ARW), consensus $1.62; Lennox International (LII), consensus 74c; NuStar Energy (NS), consensus 35c; Corinthian Colleges (COCO), consensus 2c.
News For MRK;TWX;ADP;AGN;CTSH;EL;HUM;MMP;RL;BEAM;CCE;GRA;LVLT;NDAQ;BIP;LII;NS;COCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 >>
January 28, 2016
19:02 EDTMRKMerck receives FDA approval of Zepatier
Subscribe for More Information
18:37 EDTMRKFDA approves Merck's Zepatier for chronic hepatitis C
Subscribe for More Information
07:08 EDTMRKFDA PDUFA Date for Merck's Grazoprevir/Elbasvir is January 28, 2016
07:07 EDTNDAQNasdaq reports Q4 EPS 89c, consensus 89c
Reports Q4 revenue $536M, consensus $530.16M. The company initiated 2016 non-GAAP operating expense guidance of $1.11B-$1.16B
07:04 EDTNDAQNasdaq CFO Lee Shavel to retire
Nasdaq announced that Lee Shavel, CFO and EVP, Corporate Strategy will retire, effective March 31. Shavel has accepted a position to join the board of a public company. Ron Hassen, SVP and Corporate Controller, Nasdaq, will serve as interim CFO, as the company conducts an active search to fill the role. Hassen has been with Nasdaq for nearly 15 years and previously served as interim CFO.
January 27, 2016
12:19 EDTMRKPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
11:07 EDTMRKGilead sinks as Attorney General probes pricing strategy
Shares of drugmaker Gilead (GILD) are underperforming after Massachusetts Attorney General Maura Healey warned that her office may bring an unfair commercial conduct complaint against it related to the pricing for its Hepatitis C virus treatments Sovaldi and Harvoni. UNFAIR PRICING: Healey, in a letter addressed to Gilead CEO John Martin dated January 22 that has just been made public, said that her office is considering whether Gilead's pricing strategy for Sovaldi and Harvoni may constitute an "unfair trade practice" in violation of Massachusetts law. "Because Gilead's drugs offer a cure for a serious and life-threatening infectious disease, pricing the treatment in a manner that effectively allows HCV to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether, results in massive public harm," Healey stated in her letter to Martin. Healey, who urged Gilead to adjust its pricing strategy, noted that the company has invoked the high cost and risk associated with research and development as a justification for its prices, but she said that Gilead quickly recouped its outlay to acquire Pharmasset by selling "$12.4B worth of HCV medication in the first year alone" after its deal. The AG, who said that Sovaldi costs $1,000 per pill in the U.S. but only $10 per pill in Egypt and about $4 per pill in India, contends that American taxpayers "have been footing the bill for Gilead's record profits." FREQUENT TARGET: The pricing of Gilead's hep C treatments have been the focus of significant criticism and political rhetoric in the past. In December, Senate Finance Committee Ranking Member Ron Wyden and senior committee member Chuck Grassley released the results of an 18-month investigation into the pricing and marketing of Sovaldi and Harvoni. The company "pursued a marketing strategy and final wholesale price of Sovaldi - $1,000 per pill, or $84,000 for a single course of treatment - that it believed would maximize revenue," and "fostering broad, affordable access was not a key consideration in the process of setting the wholesale prices," the senators wrote. Members of the Affordable Drug Pricing Task Force, who held a press conference last November to announce "meaningful action" to combat the "skyrocketing" costs of pharmaceuticals, specifically took aim at Sovaldi. During her campaigning efforts, presidential candidate Hillary Clinton has repeatedly decried the "outrageous" prices of specialty drugs. OTHERS TO WATCH: AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) also market or are at work on therapies for hepatitis C. PRICE ACTION: In morning trading, Gilead slid 2% to $90.35.
10:00 EDTMRK, GRAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BG Group (BRGYY) downgraded to Neutral from Outperform at Credit Suisse... Bed Bath & Beyond (BBBY) downgraded to Sell from Neutral at Citi... Bill Barrett (BBG) downgraded to Neutral from Buy at Ladenburg... Brown & Brown (BRO) downgraded to Underweight at Morgan Stanley... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at BTIG... Canadian National (CNI) downgraded to Market Perform from Outperform at Raymond James... DreamWorks (DWA) downgraded to Sell from Hold at Topeka... FirstMerit (FMER) downgraded at RBC Capital... Gentex (GNTX) downgraded to Neutral from Outperform at Baird... Haverty Furniture (HVT) downgraded to Sector Weight from Overweight at KeyBanc... Hercules Technology (HTGC) downgraded to Neutral from Buy at Compass Point... Horizon Technology (HRZN) downgraded to Market Perform from Outperform at Raymond James... Installed Building downgraded to Sector Weight from Overweight at KeyBanc... Jarden (JAH) downgraded to Neutral from Buy at Citi... K+S (KPLUF) downgraded to Sell from Hold at Berenberg... La-Z-Boy (LZB) downgraded at BB&T... Legacy Reserves (LGCY) downgraded to Market Perform from Outperform at FBR Capital... Medivation (MDVN) downgraded to Hold from Buy at Canaccord... Merck (MRK) downgraded to Neutral from Buy at BofA/Merrill... Metaldyne Performance (MPG) downgraded to Neutral from Outperform at Baird... Pier 1 Imports (PIR) downgraded to Sector Weight from Overweight at KeyBanc... Priceline (PCLN) downgraded to Neutral from Buy at Goldman... Profire Energy (PFIE) downgraded to Neutral from Buy at Chardan... Regeneron (REGN) downgraded to Hold at Canaccord... Starwood (HOT) downgraded to Underperform from Outperform at CLSA... Swiss Re (SSREY) downgraded to Equal Weight from Overweight at Morgan Stanley... TSYS (TSS) downgraded to Equal-Weight from Overweight at First Analysis... Talmer Bancorp (TLMR) downgraded to Sector Perform from Outperform at RBC Capital... TopBuild (BLD) downgraded to Sector Weight from Overweight at KeyBanc... TripAdvisor (TRIP) downgraded to Sell from Neutral at Goldman... VMware (VMW) downgraded to Hold from Buy at Summit Research... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman... WEC Energy (WEC) downgraded to Neutral from Conviction Buy at Goldman... Welltower (HCN) downgraded to Underperform from Market Perform at BMO Capital... Yamana Gold (AUY) downgraded to Neutral from Overweight at JPMorgan.
09:32 EDTMRKActive equity options trading on open
Active equity options trading on open: AAPL FB AMZN AAL BAC PCLN NFLX MRK GOOG
08:36 EDTMRKMerck downgraded to Neutral on lack of catalysts at BofA/Merrill
Subscribe for More Information
08:32 EDTNDAQIteris moves to NASDAQ
Iteris (ITI) announced that it has met the listing criteria for the NASDAQ (NDAQ) Capital Market and will move its listing from NYSE MKT to the NASDAQ Capital Market, effective with the start of trading on February 8, 2016. Iteris will continue to trade under its existing ticker symbol "ITI". Iteris common stock will trade on the NYSE MKT until the market close on February 5, 2016.
08:31 EDTMRKMerck says FDA accepts for review BLA for investigational antitoxin
Subscribe for More Information
08:29 EDTMRKMerck downgraded to Neutral from Buy at BofA/Merrill
06:03 EDTCTSHCognizant acquires KBACE Technologies, terms not disclosed
Subscribe for More Information
05:51 EDTGRAW.R. Grace downgraded to Buy from Conviction Buy at Goldman
Goldman Sachs analyst Brian Maguire downgraded W.R. Grace to Buy from Conviction Buy saying catalyst volume growth in 2016 will be weaker than previously expected due to the FCC catalyst capacity reduction. The analyst cut his price target for the shares to $103 from $110.
January 26, 2016
16:51 EDTGRAW.R. Grace, GCP combined 2016 sales view greater than $3.1B
Subscribe for More Information
16:19 EDTMMPMagellan Midstream increases dividend 3% to 78.5c
Magellan Midstream Partners has increased the partnership's quarterly cash distribution to 78.5c per unit for the period October 1 through December 31, 2015, representing the 55th distribution increase since its initial public offering in 2001. Q4 distribution is 13% higher than the Q4 FY14 distribution of 69.5c per unit and represents a 3% increase over the Q3 distribution of 76.25c.
08:26 EDTTWXTwitter in play after executive departures, says Cantor
Cantor Fitzgerald analyst Youssef Squali believes yesterday's news of several senior executives leaving Twitter (TWTR) puts the company in play and could encourage potential bidders to step forward. Twitter's current valuation and sizeable user base makes it a strategic asset for a number of potential buyers, Squali told investors last night in a research note. Potential suitors on the technology side include Alphabet (GOOG, GOOGL), Facebook (FB) and Microsoft (MSFT), the analyst contends. On the media side, Squali thinks 21st Century Fox (FOXA), Disney (DIS), Comcast (CMCSA) or Time Warner (TWX) could express interest in Twitter. No concentration of share ownership and no super-voting structure increase the odds of a buyout, Squali argues. The analyst, however, adds that the executive departures are not good news for a company in the midst of a turnaround. He maintains a Buy rating on the microblogging operator with a $45 price target. Twitter closed yesterday down 82c, or 5%, to $17.02..
07:02 EDTLIIInternational Exposition Company to hold an expo
Subscribe for More Information
06:31 EDTGRAW.R. Grace plans to initiate quarterly dividend of 17c
W. R. Grace announced that its board has approved a policy of paying a regular quarterly cash dividend at an initial annual rate of 68c per share of common stock of the company. Grace expects its board to declare the first quarterly dividend equal to 17c per share in connection with the release of Grace's first quarter 2016 earnings, with payment expected during the second quarter.
1 | 2 | 3 | 4 | 5 | 6 | 7 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use